Updated efficacy and safety results from a phase II single-arm trial (SGN35-027) evaluating the antibody-drug conjugate Adcetris (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine for the frontline treatment of patients with early-stage classical Hodgkin lymphoma showed a 98% overall response rate and a 93% complete response rate at the end of treatment.
Specific sequences of chemotherapy, targeted therapy, and immunotherapy yielded significantly different results, according to a study that utilized simulation models and real-world data to predict outcomes under different sequencing scenarios.
